BMS 561392
Alternative Names: BMS-561392; DPC 333Latest Information Update: 17 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antirheumatics; Quinolines; Small molecules
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 17 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
- 17 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in North America (PO)
- 17 Jan 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)